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RatsAbstract This study focuses on the relationship between serum levels of cholesterol and homocys-
teine with that of total antioxidant capacity in rats with thyroid dysfunction.
Adult male Wistar rats were divided into three groups, a control (euthyroid), hypothyroidism and
hyperthyroidism, each of them containing ten rats. Hypothyroidism was induced by administration
of 0.1% aminotriazole in drinking water for 3 weeks. Hyperthyroidism was induced by chronic
subcutaneous injection of L-thyroxine (100 lg/day, dissolved in 200 lL saline solution/100 g body
weight) for 3 weeks. The control and hypothyroid groups were injected subcutaneously with the
same volume of saline solution.
Results showed that hyperthyroidism is characterized by reduced serum thyroid stimulating
hormone (TSH) levels despite increased free thyroxine (FT4) and free triiodothyronine (FT3)
levels.
Signiﬁcant (p< 0.05) elevation in serum levels of total homocysteine (t-Hcy) is reﬂected by a
decrease in serum total antioxidant capacity (TAC) production in hypothyroidism comparing to
control.
There was a signiﬁcant (p< 0.05) elevation in serum levels of lipid proﬁle (cholesterol, triglycer-
ide and LDL) in hypothyroidism. Signiﬁcant (p< 0.05) reduction occurred in the levels of choles-
terol and triglyceride in hyperthyroidism. The association of hyperhomocysteinemia and lipid
abnormalities occurring in hypothyroidism may represent a dynamic atherogenic state.
ª 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Thyroid disease, namely hypothyroidism and hyperthyroid-
ism, constitutes the most common endocrine abnormality inrecent years, diagnosed either in subclinical or clinical form.
Thyroid disease is associated with various metabolic abnor-
malities, due to the effects of thyroid hormones on nearly all
major metabolic pathways.
Thyroid hormones, thyroxine (T4), and triiodothyronine
(T3) play an important role in all major metabolic pathways.
They regulate the basal energy expenditure through their effect
174 A.A.S. Salehon protein, carbohydrate, and lipid metabolism. This might be
a direct effect or an indirect effect by modiﬁcation of other
regulatory hormones such as insulin or catecholamines (Kim,
2008). Many studies reported that thyroid hormones stimulate
cholesterol synthesis by inducing 3-hydroxy-3-methyl-glutaryl
coenzyme A reductase in the liver (Cachefo et al., 2001;
Beylot, 2001). In addition thyroid hormones inﬂuence all
aspects of lipid metabolism including synthesis, mobilization,
and degradation. Furthermore, thyroid hormones affect lipo-
protein lipase activity and thus, the hydrolysis of triglycerides
into very-low density lipoprotein (VLDL) and chylomicrons
into fatty acids and glycerol (Cachefo et al., 2001). Finally,
thyroid hormones modulate lipid metabolism by upregulation
of the low density lipoprotein (LDL) receptors, which results
in enhanced catabolism of the LDL particles.
In hypothyroidism, lipoprotein lipase activity in the adipose
tissue has been found normal or decreased, in addition to
decreased hepatic lipase activity resulting in normal or high
levels of triglycerides (Abrams et al., 1981). In hyperthyroid-
ism, although lipoprotein lipase activity is usually normal
(Tan et al., 1998), an increased liver fatty acid synthesis and
oxidation are observed due to enhanced acetyl-CoA carboxyl-
ase 1 and carnitine palmitoyltransferase Ia expression leading
to increased VLDL biosynthesis (Liu and Brent, 2010). More-
over, hyperthyroidism is characterized by reduced serum TSH
levels despite increased free thyroxine (FT4) and free triiodo-
thyronine (FT3) levels.
Dyslipidemia is a common metabolic abnormality in
patients with thyroid disease, either in the overt or subclinical
forms of the disease, and constitutes the end result of the effect
of thyroid hormones in all aspects of lipid metabolism leading
to various quantitative and/or qualitative changes of triglycer-
ides, phospholipids, cholesterol, and other lipoproteins. Dysli-
pidemia also occurs due to the coexisting metabolic
abnormalities in thyroid disease including oxidative stress
and insulin resistance, which induce further or aggravate the
existing dyslipidemia, via a vice–vicious cycle (Santi et al.,
2010; Tagami et al., 2010).
Moreover, homocysteine is a marker for low thyroid and
low B vitamins (should be less than 9) so the higher total
homocysteine concentrations seen in the elderly may be caused
by many factors including malabsorption of B12 or a subopti-
mal intake of B-vitamins (especially vitamin B12), reduced
kidney function, medications that reduce the absorption of
vitamins (as in the case of H2 receptor antagonists or pro-
ton-pump inhibitors reducing B12 absorption) (Ruscin et al.,
2002) or increase in the catabolism of the vitamins (as in the
case of metformin reducing blood levels of B12 and folic acid).
Certain diseases are associated with higher homocysteine
levels, as can such lifestyle factors as smoking (Targher
et al., 2000), coffee consumption (Temple et al., 2000), and
excessive alcohol intake (Sakuta and Suzuki, 2005). Lack of
exercise, obesity (Yun et al., 2013) and stress are also associ-
ated with hyperhomocysteinemia.
Thus, the present study was carried out to investigate the
changes in lipid proﬁle associated with disturbances in serum
levels of cholesterol and homocysteine with that of total
antioxidant capacity in rats as a result of experimentally-
induced hypo- and hyperthyroidism.Material and methods
Thirty adult male Wistar rats (200–250 g) were used for the
current study after being procured from the Animal House
of El-Nile Company for Pharmaceutical Products, Cairo,
Egypt. The animals were acclimatized for 2 weeks in the
Animal House of Zoology Department, Women’s College,
Ain Shams University before induction of hypothyroidism or
hyperthyroidism in them. Five rats were housed per wire
ﬂoored cage in an air-conditioned room (22 ± 2 C) with
12 h light/dark cycle and had free access to standard labora-
tory chow diet (El Nasr Co., Cairo, Egypt) according to
National Research Council (NRC, 1977) and water ad libitum.
The protocol of this study was approved by the Department of
Zoology Council, Women’s College, Ain Shams University,
Egypt, which has an ethical authority.
Animals were divided into three groups, control animal
(euthyroid) group, hypothyroidism rat group and hyperthy-
roidism rat group, each of them containing ten rats. Hypothy-
roidism was induced by administration of 0.1% aminotriazole
(Sigma Chem. Co., St. Louis, MO, USA) in drinking water for
3 weeks as previously described by Lopez et al. (2001).
Whereas, hyperthyroidism was induced by chronic subcutane-
ous injection of L-thyroxine (100 lg/day, dissolved in 200 lL
saline solution/100 g body weight) (Sigma Chem. Co.,
St. Louis, MO, USA) for 3 weeks according to Lopez et al.
(2002). The control animal (euthyroid) group and hypothyroid
animals were injected subcutaneously with the same volume of
saline solution (0.9% NaCl). At the end of each treatment,
animals were dissected under slight anesthesia by ether, blood
samples were collected by heart puncture, centrifuged and the
sera were separated and stored at 20 C until assayed.
Estimation of serum thyroid stimulating hormone (TSH)
Thyroid stimulating hormone (TSH) was assayed by radioim-
munoassay (RIA) kit using the solid phase component system
(Phoenix Pharmaceuticals, Inc., USA) as described by Patrono
and Peskar (1987).
Estimation of serum hormonal proﬁle
Serum total triiodothyronine (T3) and total thyroxine (T4)
levels were estimated by a radioimmunoassay method kit using
solid phase component system according to Ekins (1978) and
Chopra et al. (1972). The kits were purchased from Diagnostic
Product corporation (DPC), USA. Serum free triiodothyro-
nine (FT3) and free thyroxine (FT4) levels were estimated by
a radioimmunoassay method kit using solid phase component
system according to Ekins (1978) and Siegel et al. (1978). The
kits were purchased from Phoenix Pharmaceuticals, Inc., USA.
Estimation of serum T3-uptake
T3-uptake was assayed using ELISA techniques. The kits
were purchased from Immuno-Biological Laboratories, Inc.
(IBL-America), Minneapolis, USA according to Witherspoon
et al. (1981).
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The levels of total homocysteine (t-Hcy) were assayed by the
aid of ELISA (Sandwich immunoassay technique) using
commercial kit (CUSABIO, China) according to Primus
et al. (1988).
Estimation of serum lipid proﬁle
Serum total cholesterol, triglycerides and HDL-cholesterol
were estimated enzymatically according to Watson (1960),
Fossati et al. (1982), and Freidewald et al. (1972), respectively
using commercial kits from Ran-dox, Ltd., Co. (UK).
LDL-cholesterol was calculated according to the equation of
Assmann et al. (1984) as follows:
LDL Chol: ¼ Total Chol: ½TG=5HDL Chol::Determination of total antioxidant capacity (TAC)
concentration
Total antioxidant capacity (TAC) was measured according to
the method of Koracevic et al. (2001), using EIA kit that was
purchased from Labor Diagnostika Nord Co., Germany.
Statistical analysis
Statistical deference between the means was assayed by using
analysis of variance (ANOVA) followed by Duncan’s multiple
range tests according to Snedecor and Cochran (1982).
Result and discussion
Thyroid gland function regulates a wide range of metabolic
events, it signiﬁcantly affects lipoprotein metabolism and as
a result cardio vascular disease (CVD) risk (Duntas, 2002).
Thyroid hormones affect cholesteryl ester transfer protein
and hepatic lipase activity, which are increased in hyperthy-
roidism and decreased in hypothyroidism, with consequent
changes not only in total high-density lipoprotein (HDL) but
also in HDL subfraction levels (Berti et al., 2001). Thyroid
disorders are known to inﬂuence lipid metabolism and are
common in dyslipidemic patients. Overt and subclinical hypo-
thyroidism have an adverse effect on the serum lipid proﬁle
that may predispose to the development of atheroscleroticTable 1 Changes in thyroid proﬁle levels in hypo- and hyperthyroi
Parameters Euthyroid rat group Hy
TSH (mIU/mL) 1.19 ± 0.016a 3
T4 (lg/mL) 3.72 ± 0.065
a 1
T3 (ng/mL) 62.12 ± 1.12
a 36
FT4 (ng/mL) 0.38 ± 0.005
a 0
FT3 (pg/mL) 0.71 ± 0.009
a 0
T3-uptake (%) 10.97 ± 0.42
a 5
Values are expressed as means ± S.E, n= 10.
a Signiﬁcant at p< 0.05 between the groups in the same rows.
b Signiﬁcant at p< 0.05 between the groups in the same rows.
c Signiﬁcant at p< 0.05 between the groups in the same rows.disease. In addition, levels of total and LDL cholesterol tend
to increase as the thyroid function declines. Therefore,
hypothyroidism constitutes a signiﬁcant cause of secondary
dyslipidemia. In addition, thyroid failure is accompanied
by an increase in plasma homocysteine levels with its known
adverse effect on the cardiovascular system (Bicı´kova´ et al.,
2003).
Homocysteine a type of amino acid that is naturally found
in blood plasma is not harmful at normal levels, but when its
levels are too high, health problems can result. If unhealthy
levels of homocysteine accumulate in the blood the delicate
lining of an artery (endothelium) can be damaged. Also,
homocystine can both initiate and potentiate atherosclerosis.
For example, homocysteine-induced injury to the arterial wall
is one of the factors that can initiate the process of atheroscle-
rosis, leading to endothelial dysfunction and eventually to
heart attacks and strokes (Gallai et al., 2001; Papatheodorou
and Weiss, 2007). Several studies have shown that homocyste-
ine can inﬂict damage to the arterial wall via multiple destruc-
tive molecular mechanisms (Hofmann et al., 2001; Zeng et al.,
2003; Osanai et al., 2010).
In the present study, rat was used as an animal model for
induction of hypothyroidism and hyperthyroidism .The
levels of total homocysteine, total antioxidant capacity and
correlation with the levels of cholesterol and other measured
parameters were evaluated in thyroid dysfunction.
Table 1 illustrates the changes in thyroid proﬁle levels in
hypo- and hyperthyroidism rats. In hypothyroidism rat group
there was a high signiﬁcant (p< 0.05) elevation in serum levels
of thyroid stimulating hormone (TSH) while there was a signif-
icant (p< 0.05) decrease in serum levels of total thyroxine
(TT4), total triiodothyronine (TT3), free T4 (FT4), free T3
(FT3) and T3-uptake. In relation to the euthyroid rat group,
a signiﬁcant (p< 0.05) decrease in the serum levels of TSH
was observed in the hyperthyroidism rat group. Moreover, a
signiﬁcant (p< 0.05) increase in serum levels of TT4, TT3,
FT4, FT3 and T3-uptake was noted.
The present results suggest that the changes in thyroid pro-
ﬁle levels in both hypo- and hyperthyroidism rat group may be
due to the disturbance in the hypothalamic-pituitary–thyroid
axis, the increment in the conversion of T3 to T4 or/and the
elevation in the formation of reverse T3 (rT3) concentration.
Furthermore, there was a relationship between the concentra-
tions of thyroid hormones (T3 and T4) in serum and
hyperlipidemia which is evident and the thyroid activity has
an adverse effect on all plasma lipids (Deuel, 1955). Thyroiddism rats.
pothyroidism rat group Hyperthyroidism rat group
.40 ± 0.106b 0.41 ± 0.006c
.63 ± 0.037b 8.11 ± 0.118c
.53 ± 0.79b 148.82 ± 3.47c
.17 ± 0.003b 1.02 ± 0.011c
.46 ± 0.005b 2.43 ± 0.028c
.89 ± 0.23b 19.06 ± 0.81c
Table 2 Changes in homocysteine, lipid proﬁle and total antioxidant capacity levels in hypo- and hyperthyroidism rats.
Parameters Euthyroid rat group Hypothyroidism rat group Hyperthyroidism rat group
Total Hcy (lmol/L) 10.02 ± 0.69a 12.67 ± 0.84b 9.94 ± 0.66a
Cholesterol (mg/mL) 56.72 ± 1.11a 90.35 ± 1.66b 49.21 ± 1.19c
Triglycerides (mg/mL) 69.19 ± 1.32a 102.47 ± 2.11b 48.93 ± 1.48c
HDL (mg/mL) 15.12 ± 0.63a 15.18 ± 0.65a 11.45 ± 0.51b
LDL (mg/mL) 27.76 ± 0.81a 54.68 ± 1.32b 27.97 ± 0.86a
TAC (mmol/L) 1.437 ± 0.045a 0.978 ± 0.029b 1.429 ± 0.031a
Values are expressed as means ± S.E, n= 10.
a Signiﬁcant at p< 0.05 between the groups in the same rows (lmol/L).
b Signiﬁcant at p< 0.05 between the groups in the same rows (lmol/L).
c Signiﬁcant at p< 0.05 between the groups in the same rows (lmol/L).
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lipoprotein (LDL) receptor gene expression in the liver,
enhancing LDL clearance and explaining the decreased or
increased LDL levels that were observed in hyperthyroidism
and hypothyroidism, respectively.
A signiﬁcant elevation in serum levels of total homocysteine
(Hcy), total cholesterol triglycerides and LDL was observed in
relation to the euthyroid rat group whereas a signiﬁcant
(p< 0.05) depletion occurred in the total antioxidant capacity
(TAC) in the hypothyroidism rat group but no marked
changes were observed in serum levels of HDL-C. In the
hyperthyroidism rat group, the changes in serum levels of total
homocysteine were not signiﬁcant. Further, a notable decrease
in total cholesterol, triglycerides and HDL was also observed.
In addition, no remarkable changes in serum levels of LDL-C
and TAC were noticed (Table 2). These results may be
attributed to the disturbances in the fat absorption and its
metabolism, alteration in de Novo lipogenesis, changes in the
ß-oxidation of fatty acids in the matrix of mitochondria and
disturbances in the hypothalamus–pituitary–thyroid axis
(HPTA). The obtained data in the current investigation were
in agreement with several studies that reported an overt
hypothyroidism is characterized by hypercholesterolemia and
a marked increase in low-density lipoproteins (LDL) and
apolipoprotein B (Duntas, 2002). These changes accelerate
atherosclerosis, which causes coronary artery disease (Kritz-
Silverstein et al., 2009; Rizos et al., 2011). Also, high homocys-
teine levels in the blood cause cholesterol to change to oxidized
low-density lipoprotein, which damages the arteries by crea-
tion of plaque inside artery walls (McCully, 1996). Some forms
of homocysteine have been shown to damage the inner walls of
blood vessels directly (Jakubowski, 2003). Another important
ﬁnding was the signiﬁcant correlation between serum levels
of homocysteine, total cholesterol and LDL-C with total anti-
oxidant capacity was noticed in the hypothyroidism rat group
but the correlation was not signiﬁcant in the case of hyperthy-
roidism rat group.
Altered lipid proﬁle is a well-known manifestation of
thyroid dysfunction. Both plasma LDL-C and HDL-C
increase in hypothyroidism and decrease in hyperthyroidism
(Diekman et al., 2000). These changes in the lipid proﬁle are
explained by the regulatory effect of thyroid hormones on
the activity of some key enzymes of lipoprotein metabolism.
Speciﬁcally, the thyroid hormone stimulates the hepatic de
novo cholesterol synthesis by inducing the 3-hydroxy-3-meth-
ylglutaryl-coenzyme A (HMG-CoA) reductase that catalyzesthe conversion of HMG-CoA to mevalonate, the ﬁrst step in
the biosynthesis of cholesterol. This results in an enhanced
intracellular cholesterol concentration in hyperthyroidism
and a decreased one in hypothyroidism (Duntas, 2002).
Most of the existing studies support lower total and LDL
cholesterol levels in patients with hyperthyroidism while only
a few data support no change (Yavuz et al., 2004). Lower
triglycerides, HDL, apoA1, apoB, and Lp(a) levels have been
found in patients with hyperthyroidism compared with euthy-
roid controls (Alterihy et al., 2012).
Thyroid disease is related to the development of dyslipide-
mia which is a well-known atherogenic factor. Further,
dyslipidemia induces insulin resistance oxidative stress, via a
vice–vicious cycle (Santi et al., 2010). Insulin resistance,
hypertension, inﬂammation, oxidative stress, and coagulation
deﬁcits are also promoted by thyroid disease, independently
of dyslipidemia (Biondi and Klein, 2004). The above associa-
tions support a multifactorial origin of atherosclerosis in
thyroid disease, with dyslipidemia playing an important role
(Fazio et al., 2004).
The risk of heart disease increases proportionally with
increasing TSH, even in subclinical hypothyroidism
(Rodondi et al., 2010). Hypothyroidism that is caused by
autoimmune reactions is associated with stiffening of the blood
vessels (Stamatelopoulos et al., 2009). Thyroid hormone
replacement may slow the progression of coronary heart dis-
ease by inhibiting the progression of plaques (Caparevic
et al., 2003). Moreover, treating hypothyroid patients with
thyroid hormone replacement might attenuate homocysteine
levels, an independent risk factor for cardiovascular disease.
A strong inverse relationship between homocysteine and free
thyroid hormones conﬁrms the effect of thyroid hormones
on homocysteine metabolism (Bicı´kova´ et al., 2003). Recent
investigations in humans have shown that in case of high levels
of thyroid stimulating hormone (TSH) values, there is a
linear increase in total cholesterol, LDL-C, and TGs in addi-
tion to a linear decrease in HDL-C (Asvold et al., 2007;
Alterihy et al., 2012).
Hyperhomocysteinemia, a newly emerged independent risk
factor coronary artery diseases, is one of the main factors that
cause various diseases, such as cancer, (Poirier et al., 2001)
atherosclerosis (Merkel, 2004) diabetes, (Luis et al., 2004)
and some other aged-related illnesses including Alzheimer’s
disease, (Nilsson et al., 2002). Homocysteine is formed by
demethylation of essential amino acid methionine. Thus, an
imbalance in dietary methionine may contribute to the devel-
opment of atherosclerosis by increasing homocysteine levels.
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ine, total cholesterol, triglycerides, LDL and TBARS levels in
myocardial homogenates in methionine-treated rats with a
notable decrease in HDL levels was also seen. Furthermore,
high cholesterol has been the focus of the medical community
as the cause of heart attacks and strokes. Some factors such as:
urban residence, butter consumption, hypertension and intel-
lectual work may contribute to the etiology of atherosclerosis
through their impact on serum lipid fractions (Mohamed et al.,
2008).
Oxidative stress induced by homocysteine is reﬂected by a
decrease in serum total anti-oxidant capacity. The oxidative
stress resulting from elevated serum Hcy can oxidize
membrane lipids and proteins and stimulate the activation of
NF-B, and consequently increase the expression of inﬂamma-
tory factors in vivo. Hcy can be converted to a highly reactive
thiolactone which is able to react with proteins forming-
NH-CO-adducts, thus affecting body proteins and enzymes
(Ramakrishnan et al., 2006). Such an effect may contribute
to atherogenesis by enhancing the inﬂammatory response of
the vascular endothelium (Zhang and Mild, 2004). Messarah
et al. (2007) explain the thyroid activity variation in relation
to the lipid peroxidation and the tissue contents of the
enzymatic and the non-enzymatic antioxidants and show
the occurrence of a state of oxidizing stress in relation to
hyperthyroidism. Homocysteine like sulfhydryl compound
can promote the oxidation of LDL, reduce the concentration
of HDL cholesterol in plasma by inhibiting the synthesis of
apo A-I, the main HDL apolipoprotein and increase the
serum levels of MDA (Barter and Rye, 2006). Hcy induced
lipid dysregulation is an important mechanism linking Hcy
to the development of atherosclerosis. Thyroid hormones are
physiologic modulators of both tissue oxidative stress and
protein degradation. The mechanism linking hypothyroidism
with oxidative stress is unknown. Rahbani-Nobar et al.
(2004) demonstrated the correlation between serum levels of
homocysteine, total cholesterol and LDL with total antioxi-
dant capacity in hypothyroidism and suggests that there is
an over production of free radicals in these patients that is con-
tributed to abnormalities seen in homocysteine and cholesterol
metabolism .
It is a well-established fact that thyroid hormones regulate
the expression of enzymes involved in all steps of lipid
metabolism leading to the development of qualitative and
quantitative changes of lipids, in thyroid disease. Dyslipidemia
coexists with other metabolic abnormalities, including,
hypertension, insulin resistance, and oxidative stress, all of
them being risk factors for cardiovascular disease. Also,
elevation of total plasma concentration of homocysteine
(t-Hcy) is an important and independent risk factor for cardio-
vascular disease. Additionally, hypothyroidism is possibly also
associated with an increased risk for coronary artery disease,
which may be related to atherogenic changes in the lipid proﬁle
(Alterihy et al., 2012; Yun et al., 2013).
In conclusion, a strong relationship between serum
homocysteine levels and lipid proﬁle concentrations espe-
cially the concentrations of cholesterol in hypothyroidism
may increase cardiovascular risk (CVR). So, determination
of serum levels of thyroid proﬁle is recommended in
subjects with unexplained hyperhomocysteinemia and
hypercholesterolemia.References
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